GL Stock Analysis: Globe Life | NYSE
Insurance - Life | NYSE, USA | Market Cap: 12.024m USD | 12M Return: 21.2% | US37959E1029 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 92.7M
EPS Trend: 98.7%
Qual. Beats: 0
Rev. Trend: 96.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Globe Life Inc. (NYSE: GL) is a US-based insurance provider that, through its subsidiaries, offers life and supplemental health insurance products primarily targeted at lower middle- and middle-income families. The company operates through three business segments: Life Insurance, Supplemental Health Insurance, and Investments. It is classified within the Life & Health Insurance sub-industry of the Financials sector.
Its product portfolio spans whole, term, and other life insurance, including policies for children, as well as Medicare supplement and limited-benefit supplemental health products covering conditions such as accident, cancer, critical illness, heart, and intensive care. Additional offerings include final expense, accidental death, mortgage protection, and hospital insurance. Globe Life distributes via a multi-channel approach using direct-to-consumer, exclusive independent agents, general agency independent agents, and brokers.
The Investments segment reflects the typical insurance industry model in which collected premiums are invested to generate portfolio income alongside underwriting results. The company was founded in 1900, is headquartered in McKinney, Texas, and was formerly known as Torchmark Corporation before adopting its current name in August 2019.
- Net investment income rises on higher interest rates
- Supplemental health insurance segment drives premium growth
- Direct-to-consumer distribution gains market share
| Net Income: 1.19b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.76 > 1.0 |
| NWC/Revenue: 390.4% < 20% (prev 289.4%; Δ 101.0% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.41b > Net Income 1.19b |
| Net Debt (-6.62b) to EBITDA (1.60b): -4.13 < 3 |
| Current Ratio: 22.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.2m) vs 12m ago -4.62% < -2% |
| Gross Margin: 21.19% > 18% (prev 33.81%; Δ -12.62% > 0.5%) |
| Asset Turnover: 20.55% > 50% (prev 19.46%; Δ 1.09% > 0%) |
| Interest Coverage Ratio: 11.20 > 6 (EBIT TTM 1.60b / Interest Expense TTM 143.1m) |
| A: 0.80 (Total Current Assets 25.7b - Total Current Liabilities 1.16b) / Total Assets 30.6b |
| B: 0.31 (Retained Earnings 9.37b / Total Assets 30.6b) |
| C: 0.05 (EBIT TTM 1.60b / Avg Total Assets 30.5b) |
| D: 0.28 (Book Value of Equity 6.62b / Total Liabilities 24.0b) |
| Altman-Z'' = 6.90 = AAA |
| DSRI: 1.02 (Receivables 1.09b/1.01b, Revenue 6.28b/5.94b) |
| GMI: 1.60 (GM 33.81% / 21.19%) |
| AQI: 0.41 (AQ_t 0.15 / AQ_t-1 0.36) |
| SGI: 1.06 (Revenue 6.28b / 5.94b) |
| TATA: -0.01 (NI 1.19b - CFO 1.41b) / TA 30.6b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of November 18, 2026, the stock is trading at USD 158.04 with a total of 566,142 shares traded. Over the past week, the price has changed by -3.32%, over one month by -5.84%, over three months by -11.74% and over the past year by +21.23%.
Current recommended Stop Loss: 153.10 (which is 3.1% or 1.3 ATR below the current price).
Globe Life has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy GL.
- StrongBuy: 4
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 185.5 | 17.3% |
P/E Trailing = 10.6687
P/E Forward = 9.4877
P/S = 1.9163
P/B = 1.8322
P/EG = 1.3005
Revenue TTM = 6.28b USD
EBIT TTM = 1.60b USD
EBITDA TTM = 1.60b USD
Long Term Debt = 2.67b USD (from longTermDebt, last quarter)
Short Term Debt = 317.6m USD (from shortTermDebt, last quarter)
Debt = 2.99b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.62b USD (calculated: Debt 2.99b - CCE 9.60b)
Enterprise Value = 5.41b USD (12.0b + Debt 2.99b - CCE 9.60b)
Interest Coverage Ratio = 11.20 (Ebit TTM 1.60b / Interest Expense TTM 143.1m)
EV/FCF = 9.43x (Enterprise Value 5.41b / FCF TTM 573.2m)
FCF Yield = 10.60% (FCF TTM 573.2m / Enterprise Value 5.41b)
FCF Margin = 9.13% (FCF TTM 573.2m / Revenue TTM 6.28b)
Net Margin = 18.88% (Net Income TTM 1.19b / Revenue TTM 6.28b)
Gross Margin = 21.19% ((Revenue TTM 6.28b - Cost of Revenue TTM 4.95b) / Revenue TTM)
Gross Margin QoQ = 56.51% (prev -50.26%)
Tobins Q-Ratio = 0.18 (Enterprise Value 5.41b / Total Assets 30.6b)
Interest Expense / Debt = 4.79% (Interest Expense 143.1m / Debt 2.99b)
Taxrate = 19.00% (278.1m / 1.46b)
NOPAT = 1.30b (EBIT 1.60b * (1 - 19.00%))
Current Ratio = 14.95 (Total Current Assets 25.7b / Total Current Liabilities 1.72b)
Debt / Equity = 0.45 (Debt 2.99b / totalStockholderEquity, last quarter 6.62b)
Debt / EBITDA = -4.13 (Net Debt -6.62b / EBITDA 1.60b)
Debt / FCF = -11.55 (Net Debt -6.62b / FCF TTM 573.2m)
Total Stockholder Equity = 6.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.88% (Net Income 1.19b / Total Assets 30.6b)
RoE = 19.09% (Net Income TTM 1.19b / Total Stockholder Equity 6.21b)
RoCE = 18.06% (EBIT 1.60b / Capital Employed (Equity 6.21b + L.T.Debt 2.67b))
RoIC = 4.41% (NOPAT 1.30b / Invested Capital 29.4b)
WACC = 6.06% (E(12.0b)/V(15.0b) * Re(6.60%) + D(2.99b)/V(15.0b) * Rd(4.79%) * (1-Tc(0.19)))
Discount Rate = 6.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.49 | Cagr: -7.78%
[DCF] Terminal Value 73.10% ; FCFF base≈910.3m ; Y1≈798.3m ; Y5≈645.0m
[DCF] Fair Price = 225.0 (EV 10.4b - Net Debt -6.62b = Equity 17.0b / Shares 75.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 98.74 | EPS CAGR: 15.56% | SUE: -0.15 | # QB: 0
Revenue Correlation: 96.00 | Revenue CAGR: 5.55% | SUE: -0.82 | # QB: 0
EPS current Quarter (2027-03-31): EPS=3.78 | Chg30d=-2.49% | Revisions=-73% | Analysts=10
EPS current Year (2026-12-31): EPS=15.49 | Chg30d=-1.47% | Revisions=-79% | GrowthEPS=+6.7% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=16.38 | Chg30d=-0.78% | Revisions=-31% | GrowthEPS=+5.8% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -72% (up=3, down=26)